Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 May 27;8(2):67.
doi: 10.3390/antibiotics8020067.

Use of Ceftolozane/tazobactam for the Treatment of Multidrug-resistant Pseudomonas aeruginosa Pneumonia in a Pediatric Patient with Combined Immunodeficiency (CID): A Case Report from a Tertiary Hospital in Saudi Arabia

Ahmed Zikri  1 , Kamal El Masri  2
Affiliations
Case Reports

Use of Ceftolozane/tazobactam for the Treatment of Multidrug-resistant Pseudomonas aeruginosa Pneumonia in a Pediatric Patient with Combined Immunodeficiency (CID): A Case Report from a Tertiary Hospital in Saudi Arabia

Ahmed Zikri et al. Antibiotics (Basel). .

Abstract

Infections, with multidrug-resistant Pseudomonas aeruginosa, are a major concern in the pediatric intensive care unit, especially in immunocompromised patients. Some of these strains are resistant to all beta-lactams, including carbapenems, leaving very limited treatment options remaining. These options include aminoglycosides and colistin, both of which have poor pharmacokinetic profiles with significant toxicities. Newer beta-lactam/beta-lactamase inhibitor combinations offer additional novel options to treat such infections, given their good pharmacokinetic profiles and activity against multi-drug resistant strains. Ceftolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor combination approved in 2014. The drug demonstrates good activity against multidrug-resistant P. aeruginosa strains, including those resistant to all other antibiotics. Ceftolozane/tazobactam is currently approved in adult patients 18 years and older only. There are very limited data on its pharmacokinetic profile and clinical utility in the pediatric population. We report the use of ceftolozane/tazobactam to successfully treat pneumonia caused by multidrug-resistant P. aeruginosa in a pediatric patient with combined immunodeficiency syndrome.

Keywords: Pseudomonas; ceftolozane/tazobactam; immunodeficiency; pneumonia; resistance.

PubMed Disclaimer

Conflict of interest statement

Dr. Zikri has received honorarium from Merck Sharp & Dohme for speaking at non-promotional educational activities in the Kingdom of Saudi Arabia. Dr. El Masri declares no conflict of interest.

References

    1. Rivers L., Gaspar H.B. Severe combined immunodeficiency: recent developments and guidance on clinical management. Arch Dis Child. 2015;100:667–672. doi: 10.1136/archdischild-2014-306425. - DOI - PubMed
    1. Wi Y.M., Greenwood-Quaintance K.E., Schuetz A.N., Ko K.S., Peck K.R., Song J.-H., Patel R. Activity of ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms. Antimicrob. Agents Chemother. 2018;62:e01970-17. doi: 10.1128/AAC.01970-17. - DOI - PMC - PubMed
    1. Bradley J.S., Ang J.Y., Arrieta A.C., Larson K.B., Rizk M.L., Caro L., Yang S., Yu B., Johnson M.G., Rhee E.G. Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children with Proven or Suspected Gram-Negative Infection. Pediatr. Infect. Dis. J. 2018;37:1130–1136. doi: 10.1097/INF.0000000000002170. - DOI - PubMed
    1. Aitken S.L., Kontoyiannis D.P., DePombo A.M., Bhatti M.M., Tverdek F.P., Gettys S.C., Nicolau D.P., Nunez C.A. Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient. Pediatr. Infect. Dis. J. 2016;35:1040–1042. doi: 10.1097/INF.0000000000001228. - DOI - PubMed
    1. Ang J.Y., Abdel-Haq N., Zhu F., Thabit A.K., Nicolau D.P., Satlin M.J., van Duin D. Multidrug-resistant Pseudomonas aeruginosa infection in a child with cystic fibrosis. Antimicrob. Agents Chemother. 2016;60:5627–5630. doi: 10.1128/AAC.00705-16. - DOI - PMC - PubMed

Publication types

LinkOut - more resources